The latest updates from AFAR.

Experts in the News: Barzilai, Campisi, and Kirkland on targeting senescent cells in Nature

Oct 31

Experts in the News: Barzilai, Campisi, and Kirkland on targeting senescent cells in Nature View MoreBACK

On October 24, 2017, Nature journal spotlighted several AFAR-affilated experts in an a comprehensive feature article on the growing research on targeting senescent cells through senolytic drugs in order to extend healthspan.

The article, “To stay young, kill zombie cells” explains:

When a cell enters senescence — and almost all cells have the potential to do so — it stops producing copies of itself, begins to belch out hundreds of proteins, and cranks up anti-death pathways full blast. A senescent cell is in its twilight: not quite dead, but not dividing as it did at its peak. Now biotechnology and pharmaceutical companies are keen to test drugs — known as senolytics — that kill senescent cells in the hope of rolling back, or at least forestalling, the ravages of age

The article features research and insights by: 

--Multiple grantee and Deputy Scientific Director Nir Barzilai, MD

--2012 Glenn/AFAR Breakthroughs in Gerontology Award recipient and Board President-Elect James L. Kirkland, MD, PhD

--1990 AFAR Research Grant for Junior Faculty recipient Judith Campisi, PhD

--2017 AFAR Honorary Leadership Award recipient Nathaniel “Ned” David, PhD

Read the full article here.

Nir Barzilai, MD is the Director of the NIA Nathan Shock Center of Excellence in the Basic Biology of Aging, the Paul F. Glenn Center for the Biology of Aging, and the Institute for Aging Research at Albert Einstein College of Medicine.

Judith Campisi, PhD is a Professor at the Buck Institute for Research on Aging.

James Kirkland, MD, PhD is the Director of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic.

Nathaniel “Ned” David, PhD is the Co-Founder and President  of Unity Biotechnology